{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:09:28Z","timestamp":1774649368977,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019385","name":"Kurume University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinthera.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:47:39Z","timestamp":1663289259000},"page":"1418-1426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM"],"prefix":"10.1016","volume":"44","author":[{"given":"Satoko","family":"Yoshinobu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1344-8667","authenticated-orcid":false,"given":"Nao","family":"Hasuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Tokubuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Gobaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.08.009_bib0001","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0002","doi-asserted-by":"crossref","first-page":"37735","DOI":"10.1074\/jbc.R100035200","article-title":"Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism","volume":"276","author":"Lu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0003","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile acids and FXR: novel targets for liver diseases","volume":"7","author":"Stofan","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0004","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/j.2040-4603.2020.tb00108.x","article-title":"Intestinal absorption of bile acids in health and disease","volume":"10","author":"Ticho","year":"2011","journal-title":"Compr Physiol"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0006","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cmet.2015.07.002","article-title":"The bile acid chenodeoxycholic acid increases human Brown adipose tissue activity","volume":"22","author":"Broeders","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0007","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signalising to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0008","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.clinthera.2022.08.009_bib0009","first-page":"1","article-title":"TGR5 potentiates GLP-1 secretion in response to anionic exchange resins","volume":"30","author":"Harach","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0011","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0012","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756283X14528269","article-title":"Elobixibat and its potential role in chronic idiopathic constipation","volume":"7","author":"Acosta","year":"2014","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2036.2011.04675.x","article-title":"Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation\u2014a double-blind study","volume":"34","author":"Simr\u00e9n","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0014","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/17474124.2018.1522248","article-title":"Elobixibat for the treatment of constipation","volume":"12","author":"Chedid","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-015-0070-9","article-title":"Specific inhibition of bile acid transport alters plasma lipids and GLP-1","volume":"15","author":"Rudling","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0016","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4239\/wjd.v12.i6.794","article-title":"Diabetic gastroenteropathy: an underdiagnosed complication","volume":"12","author":"Concepci\u00f3n-Zavaleta","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0017","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.23831","article-title":"Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism","volume":"52","author":"Brufau","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0018","first-page":"1501257","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0019","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","article-title":"Result of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes","volume":"29","author":"Yamakawa","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0021","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0022","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1189\/jlb.0812396","article-title":"Bile acids PKA-dependently induce a switch of the IL-10\/IL-12 ratio and reduce proinflammatory capability of human macrophages","volume":"94","author":"Haselow","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0023","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0024","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0025","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0026","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1507\/endocrj.EJ20-0201","article-title":"Fasting serum total bile acid levels are associated with insulin sensitivity, islet \u03b2-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes","volume":"67","author":"Wang","year":"2020","journal-title":"Endocr J"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0027","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41598-018-19545-1","article-title":"Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels","volume":"8","author":"Kuno","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0028","doi-asserted-by":"crossref","first-page":"e38286","DOI":"10.1371\/journal.pone.0038286","article-title":"Bile acid binding resin improves metabolic control through the induction of energy expenditure","volume":"7","author":"Watanabe","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jare.2017.11.004","article-title":"Arachidonic acid: physiological roles and potential health benefits\u2014a review","volume":"11","author":"Tallima","year":"2018","journal-title":"J Adv Res"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10557-008-6140-9","article-title":"Leukotriene signaling in atherosclerosis and ischemia","volume":"23","author":"B\u00e4ck","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2022.08.009_bib0031","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11745-997-0057-5","article-title":"Increased dietary arachidonic acid enhances the synthesis of vasoactive eicosanoids in humans","volume":"32","author":"Ferretti","year":"1997","journal-title":"Lipids"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:34Z","timestamp":1758963514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0149291822002910"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}